Navigation Links
Agendia to Present at BioCentury's Future Leaders in the Biotech Industry Conference
Date:3/24/2009

HUNTINGTON BEACH, California and AMSTERDAM, The Netherlands, March 24 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, today announced that the Company is scheduled to present at the 16th Anniversary "Future Leaders in the Biotech Industry" Conference on Thursday, April 2, 2009. Presented by BioCentury and Thomson Reuters, the Future Leaders conference has built a reputation as a major biotech investment event, matching strong companies with a select group of specialized institutional investors, investment bankers, sellside/buyside analysts, and pharmaceutical licensing executives.

    Agendia's BioCentury Presentation details are as follows:
    Event: BioCentury / Thomson Financial "Future Leaders in the Biotech
    Industry"

    Presenter: Dr. Bernhard Sixt, President & CEO
    When: Thursday, April 2, 2009 at 1:30 - 1:55 p.m.
    Breakout Session: 1:55 - 2:55 p.m., Room 502
    Where: Millennium Broadway Hotel, New York City, Room 502/303
    Address: 145 West 44th Street, New York, NY, 10036

About Agendia

Agendia is at the forefront of the personalized medicine revolution, striving to bring more effective, individualized treatments within reach of patients. Building on a cutting edge genomics platform for tumor gene expression profiling, the company's tests aim to help physicians more accurately tailor cancer treatments. The company markets four products, with several new genomic tests under development. In addition, Agendia collaborates with pharmaceutical companies to develop highly effective personalized drugs in the area of oncology. Agendia is based in Huntington Beach, California, and in Amsterdam, The Netherlands. For more information please visit http://www.agendia.com.


'/>"/>
SOURCE Agendia B.V.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Agendia Presents Data Supporting MammaPrints Predictive and Prognostic Power at 2009 St. Gallen Breast Cancer Conference
2. Agendia Appoints Seasoned Diagnostics Executive Albert A. Luderer to Supervisory Board
3. Agendia Publishes Direct Evidence That MammaPrint Predicts Benefit of Chemotherapy in Breast Cancer
4. Agendia Appoints VP of Business Development
5. Agendias Breast Cancer Test MammaPrint(R) Standard of Care at Netherlands Cancer Institute - AVL
6. Agendia Appoints New Chief Financial Officer
7. Agendia and Ferrer Announce Exclusive Agreement for Sales of Cancer Diagnostic Services in Four Major European Markets
8. Agendias MammaPrint(R) Receives Prestigious Award From Dutch Innovation Platform
9. Agendia and Agilent Announce Plans to Jointly Develop New Diagnostic Tests, Extend Supply Agreement
10. Agendia BV Appoints Clinical and Scientific Advisory Board
11. Agendia BV Announces That its Chief Research Officer Laura van t Veer has Received a 2007 Breast Cancer Research Foundation Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 2016  Liquid Biotech USA ... a Sponsored Research Agreement with The University of ... from cancer patients.  The funding will be used ... with clinical outcomes in cancer patients undergoing a ... be employed to support the design of a ...
(Date:6/24/2016)... SAN DIEGO , June 24, 2016 /PRNewswire/ ... that more sensitively detects cancers susceptible to PARP ... individual circulating tumor cells (CTCs). The new test ... of HRD-targeted therapeutics in multiple cancer types. ... therapies targeting DNA damage response pathways, including PARP, ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering ... retention in this eBook by providing practical tips, tools, and strategies for clinical ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
Breaking Biology Technology:
(Date:4/26/2016)... , April 27, 2016 ... the  "Global Multi-modal Biometrics Market 2016-2020"  report to ... ) , The analysts forecast the ... CAGR of 15.49% during the period 2016-2020.  ... number of sectors such as the healthcare, BFSI, ...
(Date:4/14/2016)... BioCatch ™, the global ... the appointment of Eyal Goldwerger as CEO. ... Goldwerger,s leadership appointment comes at a time of significant ... of its platform at several of the world,s largest ... unique cognitive and physiological factors, is a winner of ...
(Date:3/29/2016)... March 29, 2016 LegacyXChange, Inc. ... "LEGX" and SelectaDNA/CSI Protect are pleased to announce our ... in a variety of writing instruments, ensuring athletes signatures ... created collectibles from athletes on LegacyXChange will be assured ... the DNA. Bill Bollander , CEO ...
Breaking Biology News(10 mins):